Revolutionizing cancer treatment with senotherapeutics: a current perspective
Cancer Chemotherapy and Pharmacology · 2026
DOI: 10.1007/s00280-025-04856-8 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Chemotherapy and Pharmacology, 2026. Verfasst von Lakshika Singh und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, Shoolini University of Biotechnology and Management Sciences, Solan, 173229, India. Hauptthemen laut MEDLINE: Neoplasms, Senotherapeutics, Cellular Senescence, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 85 Literaturangaben.
Abstract (Originalsprache)
Cellular senescence is a double-edged sword in cancer biology, initially acting as a tumor-suppressive mechanism but later contributing to cancer progression and therapy resistance. Senescent cells, characterized by stable cell cycle arrest, secrete a complex array of bioactive molecules known as the senescence-associated secretory phenotype (SASP), which fosters chronic inflammation, disrupts tissue architecture, and promotes tumorigenesis through paracrine signaling. Accumulation of these cells in the tumor microenvironment can enhance malignancy, drive metastasis, and impair treatment outcomes. Senotherapeutics, have emerged as promising strategies for targeting senescent cells in cancer therapy. These agents selectively induce apoptosis in senescent cells while preserving normal tissues, representing a paradigm shift in oncology. Senotherapeutics can function as standalone treatments by clearing senescent tumor cells or as adjuvants to chemotherapy and radiotherapy, effectively eliminating residual therapy-induced senescent cells that may contribute to relapse. This dual approach allows for reduced treatment toxicity, improved therapeutic efficacy, and decreased tumor recurrence. Furthermore, targeting non-cancerous senescent cells may help suppress inflammation-driven tumorigenesis, slow disease progression, and enhance patient outcomes. Despite their promise, challenges remain in optimizing senotherapeutic strategies, identifying precise biomarkers, and minimizing off-target effects. This review explores the mechanisms of cellular senescence, its role in tumor dynamics, and the potential of senotherapeutics as a novel adjunct in cancer treatment. By integrating senotherapeutics with existing modalities, the field moves closer to more effective, personalized cancer interventions, warranting further preclinical and clinical investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmaceutical Sciences, Shoolini University of Biotechnology and Management Sciences, Solan, 173229, India.
- Chitkara University School of Pharmacy, Chitkara University, 174103, Himachal Pradesh, India.
- GNA School of Pharmacy, GNA University, Phagwara-Hoshiarpur Rd, Sri Hargobindgarh, Dhak Khati, Punjab, 144401, India.
- Department of Pharmacy, CGC University, Jhanjeri, 140307, Mohali, India. deepakpharmatech@gmail.com.
Zitieren
APA
Singh, L., Gaur, H., Kaur, S. D., Gandhi, H., Vihal, S., & Kapoor, D. N. (2026). Revolutionizing cancer treatment with senotherapeutics: a current perspective. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-025-04856-8
Vancouver
Singh L, Gaur H, Kaur SD, Gandhi H, Vihal S, Kapoor DN. Revolutionizing cancer treatment with senotherapeutics: a current perspective. Cancer Chemotherapy and Pharmacology. 2026. doi:10.1007/s00280-025-04856-8
BibTeX
@article{Singh2026,
author = {Singh, Lakshika and Gaur, Himisha and Kaur, Simran Deep and Gandhi, Himanshu and Vihal, Samar and Kapoor, Deepak N},
title = {Revolutionizing cancer treatment with senotherapeutics: a current perspective},
journal = {Cancer Chemotherapy and Pharmacology},
year = {2026},
doi = {10.1007/s00280-025-04856-8}
}
EUVIMED